00:00Elsewhere, in the next generation, obesity shot by Eli Lilly helped patients lose almost a quarter of their body weight in a recent study.
00:07The drug was so effective that some patients dropped out of the study because they lost so much weight.
00:14Bloomberg health reporter Madison Muller joins us to explain.
00:17Madison, just how big of a step up is this in progress for these weight loss medications?
00:23Yeah, this is a huge step up. That's exactly right.
00:25I mean, this is the next wave of therapeutics, the next generation of drugs that are, you know, the drug makers were hoping were going to be even more effective than the currently available medicines, which are Wagovi and ZepBound.
00:37And already those drugs work really well.
00:39I mean, in a lot of cases, ZepBound can help patients lose up to 20 percent of their body weight.
00:45And so that was sort of the bar for where these next generation drugs had to get higher than that in order to be considered successful by investors and by the companies who have set sort of a high bar for themselves.
00:57And so we have seen Lilly and Novo Nordisk, their rival, trying to develop these next generation compounds.
01:04Novo's really struggled with that.
01:05But this is the first time that we're seeing this late stage phase three data from Lilly's next generation drug.
01:11And it's really, you know, exceeding what investors had hoped for it.
Be the first to comment